Abstract
Background Little is known about early symptoms and symptom development in mild to moderate Covid-19 disease, and about their prognostic value. This applies for health professionals as well as for decision makers and lays but has significant impact on testing strategies and early detection. Few data have been collected in primary care so far.
Aim It was the aim of this study to extend knowledge of early symptoms as a precondition of early identification, and to gain understanding of associations between symptoms and severe courses of the disease.
Design and Settings This study was designed as a retrospective observational study in Austrian GP practices in the year 2020.
Methods Patients above 18 years with a positive SARS-CoV-2 test were included.
Data collection comprised basic demographic data, risk factors and the recording of symptoms at several points in time in the course of the illness.
Results Little more than one third of patients report symptoms generally understood to be typical for Covid-1. Most patients present with a variety of unspecific complaints. We found symptoms indicating complicated disease if present at certain points in time. The number of symptoms is likely to be a predictor for the need of hospital care. More than 50% of patients experience symptoms after 14 days.
Conclusions Underrating unspecific symptoms as possible indicators for SARS-CoV-2 infection harbours the danger of overlooking early disease. Monitoring patients during their illness using certain indicators for severe disease may help to identify patients who are likely to profit from early intervention.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
DRKS00022448
Funding Statement
None of the authors received any payments or services from a third party for any aspect oft the submitted work. The department for general medicine, Karl Landsteiner Universitaet received a grant of Euro 500 by the Styrian Academy of Family Medicine, Graz, Austria
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was given by the Commission for Scientific Integrity and Ethics, Karl-Landsteiner Private University for Health Sciences, Krems, Austria. Votum Nr: 1046/2020 13/07/20
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Completed data set was now analyzed, results and conclusions were adapted according to some changes in results. Sample size was doubled and additional conclusions could be drawn, Figure 2 was added, all tables and figure 1 were updated to results of the completed sample
Data Availability
All data referred to in the manuscript are available from: Department of General Medicine and Family Practice, Karl Landsteiner Privatuniversitaet, Krems, Austria
